A postdoc scholarship in brain tumor biology is available at the Division of Translational Cancer Research. Members of Alexander Pietras’ lab use in vivo, ex vivo, and in vitro modeling to characterize phenotypic plasticity, regulation of brain tumor stemness, mechanisms of therapeutic resistance, and stem cell niche—tumor cell interactions, primarily in high-grade glioma.
Please visit https://pietraslab.com for more information about the lab.
Johansson E, Grassi ES, Pantazopoulou V, Tong B, Lindgren D, Berg TJ, Pietras EJ, Axelson H, and Pietras A. CD44 interacts with HIF-2α to modulate the hypoxic phenotype of perinecrotic and perivascular glioma cells. Cell Rep, 2017 20(7): 1641-1653.
Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, and Holland EC. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell, 2014 Mar 6;14(3):357-69.
Tong B*, Pantazopoulou V*, Johansson E, and Pietras A. The p75 neurotrophin receptor enhances HIF-dependent signaling in glioma. Exp Cell Res, 2018 Oct 1;371(1):122-129.
Wee B*, Pietras A*, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, and Holland EC. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci Rep, 2016 Jul 26;6:25956
Candidates must have a PhD or equivalent degree in a relevant field (ideally cancer or stem cell biology), and experience and expertise in one or more of the following: cell- and molecular biology, in vivo modeling of cancer, bioinformatics. The successful candidate is expected to have first author publication(s) in journals relevant to the field, and strong communication skills in English. Candidates must be highly motivated to pursue postdoctoral studies independently within an international and interactive research group.
Formal requirements for scholarship eligibility:
The applicant should not have been employed by Lund University within the last two years in order to be able to receive a scholarship. PhD degree should not be more than three years old at the last day of applying (i.e. no earlier than Feb 11th 2017).
Placement: Division of Translational Cancer Research, Medicon Village, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
Ref No: V2019/2153
Duration: 2 years
Starting time: 2020-03-01 or later
Last day for applying: 2020-02-11
For further information please contact:
Lund University encourages both men and women to apply for the position.
• The scholarship amounts to 28400 SEK/month and is normally paid three months in advance.
• The scholarship is intended for the recipient’s own education and does not constitute compensation for work carried out for the University.
• The scholarship is a grant and therefore not subjected to tax deduction.
• The scholarship follows the regulations established by the Vice-Chancellor of Lund University (June 27th 2013; Reg. No PE 2013/356).
Application stating the reference number V 2019/2153 and containing a CV, a personal letter, proof of dissertation and relevant documents should be addressed to: firstname.lastname@example.org.
Last day of application is 2020-02-11